# Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

> **NCT04456699** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 335 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** 5-FU
- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Leucovorin/ levoleucovorin

## Key facts

- **NCT ID:** NCT04456699
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-19
- **Primary completion:** 2023-03-27
- **Final completion:** 2023-11-06
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2024-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04456699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04456699, "Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04456699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*